| Intravenously-administered, glycoPEGylated recombinant FIX with an extended terminal half-life |
| Shows good haemostatic effects when treating bleeds on-demand |
| Once-weekly prophylaxis significantly reduces annualized bleeding rates, including in patients with target joints |
| Maintains intraoperative and postoperative haemostasis |
| Well tolerated, with no evidence of FIX inhibitor formation, allergic reactions or thromboembolic complications in phase 3 clinical trials |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.